|Dr. Farid Bouzidi, PhD, MBA||
Chief Executive Officer (Interim)
Dr Bouzidi has a PhD in molecular biology and complemented his education with a MBA from EM Lyon. He has significant experience in both Pharma (Genentech) and Biotech (AC Immune), as well as entrepreneurship through successfully establishing his own consulting firm where he provided assistance to many clients including one of the largest pharma companies in the Czech Republic closing 3 M&A deals. Dr Bouzidi also has experience working with new start-ups through his activities the Pasteur Institute (2004-200) where he continues to offer expert advice
|Dr. Paolo Botti, PhD||
Chief Scientific Officer
Paolo founded ArisGen in 2006 based upon work undertaken in his academic lab. Paolo is a bio-organic chemist who trained at the University of Milan before moving to Vanderbilt University (USA) as a post-doctoral fellow in 1994.In 1999 Paolo became the principal Scientist at Gryphon Therapeutics (USA) developing novel Protein Therapeutics. In 2001 he moved back to Europe as the Director of the (R&D) Protein Synthesis group at Geneprot (Switzerland). Before returning to academia at Unige in 2005. Paolo is an inventor on 14 patents and has published numerous articles in peer reviewed journals.
|Christophe Guichard, Ms, DESCF, HBS||
Chief Financial Officer
Christophe Guichard has been working with biotechnology companies in Europe for a number of years. Prior to this he managed corporate finance activities in strong growth environments, first within KPMG/Salustro and then as CFO of Trader Classified Media, performing major M&A transactions including two IPOs (Nasdaq / Euronext and London Stock Exchange), senior debt financings, acquisitions and divestitures. Christophe graduated from EDHEC Business School, holds the DESCF (Expertise in Finance and Accounting) and the PLD from Harvard Business School.
|Duc Tran, Ingénieur ESPCI,||
Preclinical & PhI Senior Director
Duc Tran has seventeen year experience in drug discovery and drug development, working for large pharmaceutical companies (Sanofi-Aventis, Pfizer) and start-ups (Preglem, Prexton Therapeutics) and has extensive experience working across a range of target classes in multiple disease areas encompassing cardiovascular, anti-infective, urology, epigenetics, CNS and reproductive medicine, delivering a large number of projects into clinical development, up to PhIIa Proof of Concept. Duc has recently joined Arisgen in 2014 and is responsible for providing IND-enabling Preclinical, Clinical, Quality Assurance and Chemistry, Manufacturing and Control (CMC) leadership for the drug development programs to support regulatory submission.
Duc graduated from the French Grandes Ecoles d’ingénieurs ESPCI in Physics, Chemistry and Biology. He also holds a MSc degree in organic and bioorganic chemistry from Paris VI and is a PRINCE2 registered Project Manager. Duc has published sixteen articles in peer reviewed journals and is a named inventor on six patents.
|Dr. Sylvie Tchertchian, PhD||
Preclinical Research Director
Sylvie holds a Ph.D. in Organic Chemistry having trained at the University of Grenoble, France, before moving to Geneva for a postdoctoral position at the University of Geneva in the field of organometallic chemistry and related synthetic applications. In 2004 Sylvie joined GeneProt as Scientist with a research focus on peptide chemistry and chemical ligation. Sylvie joined ArisGen in 2006 and is responsible for pre-clinical research developing and validating novel oral peptide delivery formulations.
|Dr. Patrice Nury, PhD||
CMC Project Leader
Patrice holds a Ph.D. in Organic Chemistry having trained at the University of Geneva. Prior to joining Arisgen, Patrice held several positions of increasing responsibility in process development and API manufacture with Carbogen-Amcis. He has developed numerous multi-steps synthetic pathways for organic compounds for both discovery and development programmes as well as synthesis, process development and scale-up of APIs for clinical trails under GMP. Patrice joined Arisgen in 2007 and is responsible for development CMC.